Jazz Pharmaceuticals (JAZZ) Leases (2010 - 2026)

Jazz Pharmaceuticals' Leases history runs 15 years deep, the most recent figure standing at $55.8 million for Q1 2026.

• In Q1 2026, Leases rose 13.46% year-over-year to $55.8 million; the TTM figure through Mar 2026 stood at $55.8 million (up 13.46% YoY), while the FY2025 annual figure was $58.9 million, up 9.92% from the prior year.
• Leases was $55.8 million for Q1 2026 at Jazz Pharmaceuticals, down from $58.9 million in the prior quarter.
• In the past five years, Leases ranged from a high of $83.4 million in Q1 2022 to a low of $49.2 million in Q1 2025.
• Historically, Leases has averaged $66.9 million across 5 years, with a median of $65.3 million in 2023.
• Biggest YoY gain for Leases was 1328.71% in 2022; the steepest drop was 33.66% in 2022.
• A 5-year view of Leases shows it stood at $73.3 million in 2022, then slipped by 10.89% to $65.3 million in 2023, then decreased by 18.0% to $53.6 million in 2024, then climbed by 9.92% to $58.9 million in 2025, then slipped by 5.26% to $55.8 million in 2026.
• The last three Leases figures came in at $55.8 million (Q1 2026), $58.9 million (Q4 2025), and $61.2 million (Q3 2025), per Business Quant data.